Antisense modulation of src-c expression

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of src-c. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding src-c. Methods of using these compounds for modulation of src-c expression and for treatment of diseases associated with expression of src-c are provided.

What is claimed is:  
     
         1 . A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding a 5′UTR, 3′UTR, coding region, intron region, exon region, stop codon, intron:exon junction, exon:exon junction, or 5′ mRNA variant of src-c, wherein said compound specifically hybridizes with and inhibits the expression of src-c.  
     
     
         2 . The compound of  claim 1  which is an antisense oligonucleotide.  
     
     
         3 . The compound of  claim 2  wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 29, 30, 35, 44, 45, 46, 48, 53, 54, 56, 57, 58, 60, 61, 62, 63, 64, 65, 67, 69, 70, 71, 72, 73, 76, 77, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 52, 68, 78, 108, 110, 113, 118, 120, 121, 124, 125, 128, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 143, 145, 146, 147, 148, 151, 155, 157, 158, 163, 164, 167, 168 or 169.  
     
     
         4 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
     
     
         5 . The compound of  claim 4  wherein the modified internucleoside linkage is a phosphorothioate linkage.  
     
     
         6 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified sugar moiety.  
     
     
         7 . The compound of  claim 6  wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.  
     
     
         8 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified nucleobase.  
     
     
         9 . The compound of  claim 8  wherein the modified nucleobase is a 5-methylcytosine.  
     
     
         10 . The compound of  claim 2  wherein the antisense oligonucleotide is a chimeric oligonucleotide.  
     
     
         11 . A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding src-c.  
     
     
         12 . A composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         13 . The composition of  claim 12  further comprising a colloidal dispersion system.  
     
     
         14 . The composition of  claim 12  wherein the compound is an antisense oligonucleotide.  
     
     
         15 . A method of inhibiting the expression of src-c in cells or tissues comprising contacting said cells or tissues with the compound of  claim 1  so that expression of src-c is inhibited.  
     
     
         16 . A method of treating an animal having a disease or condition associated with src-c comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of  claim 1  so that expression of src-c is inhibited.  
     
     
         17 . The method of  claim 16  wherein the disease or condition is a hyperproliferative disorder.  
     
     
         18 . The method of  claim 17  wherein the hyperpriliferative disorder is cancer.  
     
     
         19 . The method of  claim 18  wherein the cancer is breast, colon, pancreatic, lung, ovarian, esophageal, neuroblastoma, retinoblastoma or Kaposi's sarcoma.  
     
     
         20 . The method of  claim 16  wherein the disease or condition is aberrant bone remodeling.